Buzdar A U, Esparza L, Natale R, Cody R, Calzone K, Benson A B, Sheehan T, Berry W
University of Texas, M.D. Anderson Cancer Center, Houston 77030.
Am J Clin Oncol. 1994 Oct;17(5):417-21. doi: 10.1097/00000421-199410000-00012.
This investigation was designed with the objective of improving on currently available antiemetic regimens to counteract the disabling side effects of cancer chemotherapy. The combination of lorazepam, dexamethasone, and promethazine was compared with dexamethasone and promethazine without lorazepam in a double-blind crossover study. The initial study population consisted of 92 women (most with breast cancer) and 7 men; all received moderately or highly emetogenic chemotherapy. Complete data for both periods of therapy were available for 73 of these patients. Crossover analysis showed a highly significant effect of lorazepam in reducing the severity of nausea (p = .003); the severity of vomiting was also reduced, but less dramatically (p = .051). The frequency of all degrees of nausea and vomiting was less with lorazepam, but the difference was not statistically significant. It is concluded that lorazepam added to dexamethasone and promethazine provides an effective regimen for counteracting the emetic side effects of cancer chemotherapy.
本研究旨在改进现有的止吐方案，以对抗癌症化疗令人不适的副作用。在一项双盲交叉研究中，将劳拉西泮、地塞米松和异丙嗪的联合用药与不含劳拉西泮的地塞米松和异丙嗪进行了比较。初始研究人群包括92名女性（大多数为乳腺癌患者）和7名男性；所有患者均接受中度或高度致吐性化疗。其中73例患者可获得两个治疗阶段的完整数据。交叉分析显示，劳拉西泮在减轻恶心严重程度方面具有高度显著的效果（p = 0.003）；呕吐严重程度也有所降低，但降幅较小（p = 0.051）。使用劳拉西泮时，各种程度恶心和呕吐的发生率较低，但差异无统计学意义。得出的结论是，在使用地塞米松和异丙嗪的基础上加用劳拉西泮，为对抗癌症化疗的呕吐副作用提供了一种有效的方案。
